<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018730</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F30</org_study_id>
    <nct_id>NCT03018730</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)</brief_title>
  <official_title>An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label switch over study to assess the safety and efficacy of PRX-102.
      Patients treated with agalsidase alfa for at least 2 years and on a stable dose (&gt;80%
      labelled dose/kg) for at least 6 months. Patients will be screened and evaluated over 3
      months while continuing on agalsidase alfa. Following the screening period, the patient will
      be enrolled and switched from their agalsidase alfa treatment to receive intravenous (IV)
      infusions of PRX-102 1 mg/kg every two weeks for 12 months. No more than 25% of treated
      patients will be female.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent anti-PRX-102 antibodies</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean annualised change in eGFR</measure>
    <time_frame>Every 2 weeks for 12 months</time_frame>
    <description>Mean annualised change in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass Index (g/m2) preferably by MRI</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
    <description>Left Ventricular Mass Index (g/m2) preferably by MRI (ECG can be used as an alternative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lyso-Gb3</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Gb3</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Lyso-Gb3</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein/Creatinine ratio</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
    <description>Protein/Creatinine ratio spot urine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of pain medication use</measure>
    <time_frame>Every 2 weeks for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise tolerance (Stress Test)</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Brief Pain Inventory (BPI)</measure>
    <time_frame>Every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mainz Severity Score Index (MSSI)</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life EQ-5D-5L</measure>
    <time_frame>Every 6 months for 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>PRX-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 infusion every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRX-102</intervention_name>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
    <arm_group_label>PRX-102</arm_group_label>
    <other_name>pegunigalsidase alfa</other_name>
    <other_name>Recombinant human alpha galactosidase-A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-60 years

          2. A documented diagnosis of Fabry disease

          3. Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less
             than lower limit of normal according to laboratory range and one or more of the
             characteristic features of Fabry disease i. Neuropathic pain ii. Cornea verticillata
             iii. Clustered angiokeratoma

          4. Females: historical genetic test results consistent with Fabry mutations, or in the
             case of novel mutations a first degree male relative with Fabry disease, and one or
             more of the characteristic features of Fabry disease i. Neuropathic pain ii. Cornea
             verticillata iii. Clustered angiokeratoma

          5. Treatment with agalsidase alfa for at least 2 years and on a stable dose (&gt;80%
             labelled dose/kg) for at least 6 months

          6. eGFR ≥ 40 ml/min/1.73 m2 by CKD-EPI equation

          7. Availability of at least 2 historical serum creatinine evaluations since starting
             agalsidase alfa treatment and not more than 2 years

          8. Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method

        Exclusion Criteria:

          1. History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase alfa

          2. History of renal dialysis or transplantation

          3. History of acute kidney injury in the 12 months prior to screening, including
             specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and
             vasculitic renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as
             well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal
             obstructive nephropathy)

          4. Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             therapy initiated or dose changed in the 4 weeks prior to screening

          5. Urine protein to creatinine ratio (UPCR) &gt; 0.5 g/g and not treated with an ACE
             inhibitor or ARB

          6. Known history of hypersensitivity to Gadolinium contrast agent

          7. Females who are pregnant, planning to become pregnant during the study, or are breast
             feeding

          8. Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period
             before screening

          9. Congestive heart failure NYHA Class IV

         10. Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period
             before screening

         11. Presence of any medical, emotional, behavioral or psychological condition that, in
             the judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Chertkoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mali Szlaifer, MS</last_name>
    <phone>972(0)4-902-8100</phone>
    <phone_ext>180</phone_ext>
    <email>malis@protalix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Nicholls, MD</last_name>
      <phone>61393427000</phone>
      <email>kathy.nicholls@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Kathleen Nicholls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael L West, MD</last_name>
      <phone>9024734023</phone>
      <email>mlwest@dal.ca</email>
    </contact>
    <investigator>
      <last_name>Michael L West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ales Linhart, MD</last_name>
      <phone>420224962605</phone>
      <email>ales.linhart@lf1.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Ales Linhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Wanner, MD</last_name>
      <phone>49931020139030</phone>
      <email>wanner_c@klinik.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Wanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amseterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CEM Hollak, MD</last_name>
      <phone>31205666071</phone>
      <email>c.e.hollak@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>CEM Hollak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla Tøndel, MD</last_name>
      <phone>4755973859</phone>
      <email>camilla.tondel@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Camilla Tøndel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatriz Escuder</last_name>
      <phone>34 976 765 500</phone>
      <email>bea.escuderazuara@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Giraldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Deegan, MD</last_name>
      <phone>441223245151</phone>
      <email>patrick.deegan@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Patrick Deegan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derralynn Hughes, MD</last_name>
      <phone>44 207 472 6588</phone>
      <email>rmgvdah@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Derralynn Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Jovanovic, MD</last_name>
      <phone>441612064365</phone>
      <email>ana.jovanovic@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ana Jovanovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 10, 2017</lastchanged_date>
  <firstreceived_date>January 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
